中国上海HIV-1耐药特征:2017至2021年回顾性研究
该研究对2017年1月至2021年12月上海接受ART的8669例HIV感染者进行基因型耐药检测,分析获得性HIV-1耐药(ADR)的流行率与特征。鉴定出10种HIV-1亚型/流行重组型,主要为CRF01_AE(46.8%)、CRF07_BC(35.7%)、B(6.4%)、CRF55_01B(2.8%)和CRF08_BC(2.4%)。ADR流行率为48%(389/811),常见耐药突变导致对拉米夫定、恩曲他滨、依非韦伦和奈韦拉平高水平耐药。
要点
- ADR流行率为48%(389/811),主要亚型为CRF01_AE(46.8%)和CRF07_BC(35.7%)。
- 常见NRTI相关突变为M184V/I/L、S68G/N/R和K65R/N,NNRTI相关突变为V179D/E/T/L、K103N/R/S/T、V106M/I/A和G190A/S/T/C/D/E/Q。
- 上述突变导致对拉米夫定、恩曲他滨、依非韦伦和奈韦拉平高水平耐药,且耐药突变谱在不同亚型间显著不同。
核心结论
- 研究揭示了上海HIV-1亚型特征和耐药突变谱,为HIV感染者的临床治疗和管理提供重要指导。
研究设计与样本
- 一项流行病学研究,纳入2017年1月至2021年12月上海接受ART的HIV感染者,共8669例PLWH接受基因型耐药检测,使用斯坦福大学HIV耐药数据库程序鉴定耐药突变。
主要发现
- 鉴定出10种HIV-1亚型/流行重组型,主要为CRF01_AE(46.8%)、CRF07_BC(35.7%)、B(6.4%)、CRF55_01B(2.8%)和CRF08_BC(2.4%)。
- ADR流行率为48%(389/811)。
- 常见NRTI相关突变为M184V/I/L、S68G/N/R和K65R/N,常见NNRTI相关突变为V179D/E/T/L、K103N/R/S/T、V106M/I/A和G190A/S/T/C/D/E/Q。
- 上述耐药突变导致对拉米夫定、恩曲他滨、依非韦伦和奈韦拉平高水平耐药。
- 耐药突变谱在不同亚型间显著不同。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HIV-1 drug resistance is a huge challenge in the era of ART. OBJECTIVES: To investigate the prevalence and characteristics of acquired HIV-1 drug resistance (ADR) in Shanghai, China. METHODS: An epidemiological study was performed among people living with human immunodeficiency virus (PLWH) receiving ART in Shanghai from January 2017 to December 2021. A total of 8669 PLWH were tested for drug resistance by genotypic resistance testing. Drug resistance mutations (DRMs) were identified using the Stanford University HIV Drug Resistance Database program. RESULTS: Ten HIV-1 subtypes/circulating recombinant forms (CRFs) were identified, mainly including CRF01_AE (46.8%), CRF07_BC (35.7%), B (6.4%), CRF55_01B (2.8%) and CRF08_BC (2.4%). The prevalence of ADR was 48% (389/811). Three NRTI-associated mutations (M184V/I/L, S68G/N/R and K65R/N) and four NNRTI-associated mutations (V179D/E/T/L, K103N/R/S/T, V106M/I/A and G190A/S/T/C/D/E/Q) were the most common DRMs. These DRMs caused high-level resistance to lamivudine, emtricitabine, efavirenz and nevirapine. The DRM profiles appeared to be significantly different among different subtypes. CONCLUSIONS: We revealed HIV-1 subtype characteristics and the DRM profile in Shanghai, which provide crucial guidance for clinical treatment and management of PLWH.
引用
- Zhang M, Ma Y, Wang G, et al. The profile of HIV-1 drug resistance in Shanghai, China: a retrospective study from 2017 to 2021. J Antimicrob Chemother. 2024. PMID: 38300833. doi:10.1093/jac/dkad370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。